Close Window
Aetna Aetna
Clinical Policy Bulletin:
Capsule Endoscopy
Number: 0588


Policy

Aetna considers capsule endoscopy (e.g., Endocapsule) medically necessary for the following indications:

  1. For evaluation of locoregional carcinoid tumors of the small bowel in persons with carcinoid syndrome; or
  2. For evaluation of persons with celiac disease with a positive serology and negative biopsy; or
  3. For reevaluation of persons with celiac disease who remain symptomatic despite treatment and there is no suspected or confirmed gastrointestinal obstruction, stricture, or fistulae; or
  4. For initial diagnosis in persons with suspected Crohn's disease (abdominal pain or diarrhea plus one or more signs of inflammation (fever, elevated white blood cell count, elevated erythrocyte sedimentation rate, or bleeding) without evidence of disease on conventional diagnostic tests, including small-bowel follow-through or abdominal CT scan/CT enterography and upper and lower endoscopy (esophago-gastro-duodenoscopy (EGD) and colonoscopy); or
  5. For reevaluation of persons with Crohn's disease who remain symptomatic despite treatment and there is no suspected or confirmed gastrointestinal obstruction, stricture, or fistulae; or 
  6. For investigating suspected small intestinal bleeding in persons with objective evidence of recurrent, obscure gastrointestinal bleeding (e.g., persisent or recurrent iron-deficiency anemia and/or persisent or recurrent positive fecal occult blood test, or visible bleeding) who have had upper and lower gastrointestinal endoscopies within the past 12 months (EGD and colonoscopy) that have failed to identify a bleeding source; or
  7. For surveillance of small intestinal tumors in persons with Lynch syndrome, Peutz-Jeghers syndrome and other polyposis syndromes affecting the small bowel; or 
  8. For screening or surveillance of esophageal varices.

Capsule endoscopy is contraindicated and considered experimental and investigational because of insufficient evidence in the peer-reviewed literature in persons with known or suspected gastrointestinal obstruction, strictures, or fistulae.

Aetna considers capsule endoscopy of the intestine experimental and investigational for evaluating abdominal pain because of insufficient evidence in the peer-reviewed literature unless one or more of the above-listed criteria are met.

Aetna considers capsule endoscopy experimental and investigational for all other indications including the following because of insufficient evidence in the peer-reviewed literature (not an all inclusive list):

  • Repeat use to verify the effectiveness of surgery
  • Use as a screening test (other than esophageal varices)
  • Use as an initial test in diagnosing gastrointestinal bleeding
  • Use for colorectal cancer screening
  • Use for evaluating the colon
  • Use for evaluating diseases involving the esophagus other than esophageal varices
  • Use for follow-up of persons with known small bowel disease other than Crohn's disease
  • Use in confirming pathology identified by other diagnostic means
  • Use in evaluating the stomach
  • Use in investigating celiac sprue, duodenal lymphocytosis, recurrent intussusception, small bowel neoplasm, or suspected irritable bowel syndrome.

Aetna considers the Agile patency capsule experimental and investigational for evaluating patency of the gastrointestinal tract before wireless capsule endoscopy, and for all other indications because of insufficient evidence in the peer-reviewed literature.



Background

According to guidelines from the American Gastroenterological Association (2001), the current standard for diagnosing the source of small intestinal bleeding is push enteroscopy, in which a 4-foot long tube out-fitted with a small video camera is inserted down the esophagus, through the stomach and into the first third of the small intestine. In many cases, a definitive diagnosis cannot be made because the imaging tools cannot reach far enough into the digestive tract to find the problem. Radiologic examination of the small bowel with barium (enteroclysis) may be uncomfortable, time-consuming, and is incapable of detecting completely flat lesions of the small intestine (e.g., arteriovenous malformations).

In August 2001, the U. S. Food and Drug Administration (FDA) cleared for marketing a swallowable capsule containing a small camera that snaps pictures twice a second as it passes through the small intestine. The FDA classified the capsule, called the Given Diagnostic Imaging System (Given Imaging Ltd., Yoqneam, Israel), as a Class II device that is subject only to general regulatory controls. The capsule, marketed as the PillCam SB (previously marketed as M2A™), has a clear end that allows the camera to view the lining of the small intestine. In addition to the camera, the wireless capsule, about the size of a large vitamin pill, contains a lighting system and a transmitter that will send images from inside the intestine to video monitors, allowing doctors to detect sources of bleeding in the small intestine. FDA cleared the device for use along with, not as a replacement for, other endoscopic and radiological evaluations of the small intestine. The capsule was not studied in the large intestine.

When swallowed, the device travels down the digestive tract at about the same speed as food, propelled by peristalsis, and takes 2 to 3 hours to pass through. Once the device reaches the colon, things slow down, and the disposable device is eliminated like any solid waste within a few days.

The downside to this technology is that the images may not match fiber-optic endoscopes for detail, and concerns have been raised that the camera's view may be obscured by bubbly saliva or green bile. The capsule cannot be stopped or steered to collect close-up details of the small intestine's millions of interior wrinkles where ailments often occur. Nor is it fitted with surgical tools like a conventional endoscope to take biopsies or treat bleeding lesions or remove polyps. If a lesion requiring invasive therapy is found on capsule endoscopy, then the patient will need to undergo surgery with intra-operative endoscopy. In addition, if an abnormality is seen on capsule endoscopy, there is no good way to define its location within the small intestine. Fleischer (2002) has noted that, with capsule endoscopy, “the pylorus is usually seen, and in many patients the ileocecal valve can be demonstrated, but apart from a rough estimate linked to 'time beyond the pylorus' or 'time in front of the ileocecal valve', specific localization is not possible.”

By contrast, push enteroscopy has the advantages of being able to perform biopsies and offer therapy. If capsule endoscopy is performed without a prior push enteroscopy, a push enteroscopy will still need to be performed in most cases since a negative capsule endoscopy may not exclude a lesion, and a lesion observed on capsule examination may be within reach of the enteroscope (Faigel and Fennerty, 2002).

In a study submitted to the FDA, the Given Imaging Diagnostic System detected physical abnormalities in 12 of 20 patients with suspected small intestinal disorders, while push enteroscopy detected physical abnormalities in 7 of 20 patients. All patients included in the trial had previously undergone gastrointestinal endoscopies and radiological procedures to identify the source of their small intestinal disorders, without a conclusive diagnosis. In total, 14 lesions were detected in 13 of the 20 patients participating in the clinical trials using either the Given Imaging Diagnostic System, push enteroscopy or surgical techniques. The Given Imaging Diagnostic System detected 12 of the 14 lesions, while push enteroscopy detected 7 of 14. The investigators also noted that the Given system was able to identify sources of bleeding in 5 cases that were beyond the reach of the traditional enteroscope.

Costamagna et al (2002) compared the performance of capsule endoscopy to upper gastrointestinal barium radiography series with small bowel follow through in 20 patients, including 13 patients with obscure gastrointestinal bleeding, 3 patients with suspected Crohn's disease, 1 patient with suspected sarcoma recurrence, 1 patient with diarrhea, 1 patient with familial adenomatous polyposis, and 1 patient with small intestine polyposis. The rates of a “diagnostic” test were higher for capsule endoscopy (45 %) than for barium examination (27 %), although no test was performed to determine whether this difference was statistically significant. Among the subset of 13 patients with obscure gastrointestinal bleeding, the rates of a diagnostic test were statistically significantly higher for capsule endoscopy (30 %) than for the barium study (5 %); however, the study does not describe how this statistical analysis was performed.

This study has been criticized on several grounds (see, e.g., Faigel and Fennerty, 2002). First, the small heterogenous population included in this study makes it difficult to discern the role of this new technology in clinical practice. Second, the study does not evaluate all relevant competing technologies; specifically, the study does not examine how capsule endoscopy performs in comparison to enteroclysis or push enteroscopy; the latter may have been a more appropriate endoscopic standard for comparison. Third, the study chose to report on “diagnostic yield” because no gold standard study was performed; diagnostic yield cannot differentiate true from false positives or true from false negatives. Two studies reported higher diagnostic yields with capsule endoscopy than push enteroscopy in small groups of patients with chronic gastrointestinal bleeding. Lewis and Swain (2002) reported on the results of a pilot study of capsule endoscopy and push enteroscopy in 21 adult patients with obscure gastrointestinal bleeding whose source was not uncovered with EGD, colonoscopy or small bowel follow through. Capsule endoscopy was able to identify a bleeding source in 11 patients (55 %), whereas push enteroscopy was able to identify a bleeding source in 6 patients (30 %) (p = 0.0625). In Germany, Ell et al (2002) reported on a comparison of capsule endoscopy to push enteroscopy in 32 patients with chronic gastrointestinal bleeding. Push enteroscopy revealed definite bleeding sites in 9 patients (28 %), including angiodysplasia in 7 patients, small intestine cancer in 1 patient, and lymphoma in 1 patient. Capsule endoscopy detected definite bleeding sites in 21 patients (66 %), including angiodysplasia in 17 patients, malignant stenoses in 2 patients, and inflammatory small-intestine disease in 2 patients. Questionable bleeding sources were seen on push enteroscopy in 3 additional patients (9 %) and using capsule endoscopy in an additional 7 patients (22 %).

Much of the clinical evidence on capsule endoscopy has been presented in the form of abstracts rather than as peer-reviewed published clinical studies. As no study has compared capsule endoscopy to surgical enteroscopy or some other reliable external criterion (i.e., gold standard), the sensitivity, specificity, and predictive values of capsule endoscopy are unknown. In addition, no study has reported on the effect of capsule endoscopy on resolution of bleeding or other relevant clinical outcomes.

In the acute setting, capsule endoscopy is not a substitute for tagged red cell scintigraphy or angiography, because capsule endoscopy takes 8 hours to complete with the results generally not available until the following day.

The BlueCross BlueShield Technology Evaluation Center (2003) evaluated the evidence supporting the use of capsule endoscopy for diseases of the small intestine other than obscure gastrointestinal bleeding. The assessment identified no randomized controlled clinical studies of capsule endoscopy for these indications. The assessment identified 3 published studies (Fireman et al, 2003; Herrerias et al, 2003; Eliakim et al, 2003), involving a total of 58 patients, that prospectively examined the use of capsule endoscopy for initial diagnosis of suspected Crohn's disease when all conventional diagnostic tests, including small-bowel follow-through, have failed to reveal bowel lesions suggestive of Crohn's disease. An additional 41 patients were included in 2 abstract reports and case reports (Sant'anna et al, 2003; Bloom et al, 2003; Costamanga et al, 2003; Chong et al, 2003; Liangpunsakul et al, 2003). The assessment concluded that “[t]hese studies provide consistent evidence that wireless capsule endoscopy may demonstrate small-bowel lesions suggestive of Crohn's disease in a significant proportion of patients ranging from 43 to 71 % when all other conventional tests have been negative. Furthermore, patients in these studies diagnosed with Crohn's disease by wireless capsule endoscopy were reported to improve after treatment for Crohn's disease, which represents an improvement in health outcomes.”

The assessment did not find sufficient evidence to support the use of capsule endoscopy for other indications, including initial diagnosis of irritable bowel syndrome, celiac sprue, small bowel neoplasm, or intestinal polyposis syndrome, or follow-up of persons with known small bowel diseases. The assessment identified 1 published study, involving 20 patients, that examined the diagnostic yield of capsule endoscopy in persons with suspected irritable bowel syndrome, but none of the subjects had significant findings on capsule endoscopy (Bardan, 2003). The assessment found that the evidence for all remaining indications was limited to abstracts and case reports.

An assessment by the National Institute for Clinical Excellence (2004) found adequate evidence to support the use of capsule endoscopy, but that “[c]linicians should consider the use of other investigations prior to wireless capsule endoscopy …” The assessment noted that the main indication for this procedure is obscure gastrointestinal bleeding, which is defined as bleeding of unknown origin that persists or recurs after a negative initial endoscopy. The assessment noted that capsule endoscopy has also been used in the diagnosis and evaluation of Crohn's disease. The assessment noted that some studies have reported a higher diagnostic yield (proportion of patients identified with an apparent abnormality) than the comparator test. The assessment noted, however, in most cases, patients had undergone extensive prior investigations, which would be likely to decrease the apparent diagnostic yield for the comparator procedures. The assessment stated that “[i]t was not possible to determine the relative diagnostic performance (ability to detect correctly both the presence and absence of disease) of wireless capsule endoscopy compared with alternative conventional diagnostic tests” in the assessment of obscure gastrointestinal bleeding. Similarly, with respect to diagnosis of Crohn's disease, the assessment found that the available evidence “is not of sufficient quantity and quality to determine the relative diagnostic performance of wireless capsule endoscopy compared with alternative conventional diagnostic tests in diagnosing unselected patients with suspected Crohn's disease.”

The American Gastroenterological Association position statement on OGIB (Raju et al, 2007) stated that patients with occult gastro-intestinal (GI) blood loss and iron deficiency anemia and negative workup on EGD and colonoscopy need comprehensive evaluation, including capsule endoscopy to identify an intestinal bleeding lesion.

An assessment by the Belgian Health Care Knowledge Center (KCE) (Poelmans et al, 2006) recommended capsule endoscopy in patients with obscure GI bleeding “when a previous ileocolonoscopy and esophagogastroduodenoscopy were negative.” The assessment found that, “[a]t present, the available evidence is not of sufficient quantity and quality to determine the relative diagnostic performance of CE compared with alternative conventional diagnostic tests in diagnosing patients with CD [Crohn's disease], intestinal polyposis and celiac disease. No conclusions can be made as to whether CE is an effective alternative to other tests. Further research is warranted to determine the place of CE in the management algorithm of OGIB [obscure GI bleeding] and on other potential indications for CE such as CD, intestinal polyposis and celiac disease.”

The main limitations of capsule endoscopy in the assessment of small bowel Crohn’s disease are the lack of uniform criteria for diagnosing Crohn’s disease, inability to allow for tissue acquisition or therapeutic intervention, and the risk for capsule retention. Capsule retention in Crohn’s disease patients resulting from underlying small bowel strictures is a major concern. Retained capsules may require surgery in patients that may otherwise have not required surgery. A preingestion radiologic study (CT or small bowel follow through) is recommended because asymptomatic strictures occur in a substantial proportion of patients with Crohn’s disease. Patients with obstructive symptoms or with endoscopic and radiographic evidence of small bowel narrowing in the setting of Crohn’s disease should not undergo capsule endoscopy.

The American College of Radiology appropriateness criteria for Crohn’s disease (2008) state that wireless capsule endoscopy is likely to play an increasing role in the early diagnosis of Crohn’s disease. However, because of a 5 percent incidence of capsule retention proximal to unsuspected strictures, imaging studies, such as small-bowel follow through, are likely to remain an important screening tool prior to capsule endoscopy examinations. The guidelines state that CT is the initial imaging technique of choice in suspected Crohn’s disease complications, and shows considerable promise in initial diagnosis and estimation of disease severity. Other guidelines similarly recommend reserving capsule endoscopy to patients with suspected Crohn’s disease and negative workup, where strictures have been excluded (see, e.g., World Gastroenterology Organization Global Guidelines, 2009; British Society of Gastroenterology, 2008).  There is a lack of prospective studies demonstrating that use of capsule endoscopy for followup of persons with established Crohn’s disease alters management such that clinical outcomes are improved. Evidence has focused on diagnostic yield. A retrospective study by Long, et al. (2011) reported on changes in management after capsule endoscopy; however, the study does not report on whether clinical outcomes are improved. The European Consensus Statement that was cited states that capsule endoscopy “has a potential role” in assessment of mucosal healing after drug therapy.” It should be noted that this recommendation is based upon low quality evidence, evidence level 4: “Case–control study, poor or nonindependent reference standard”; and a grade C recommendation based upon these studies. The guidelines do not endorse a routine role for capsule endoscopy for followup; rather capsule endoscopy “should only be considered if ileocolonoscopy is contraindicated or unsuccessful,” a recommendation that is based upon limited evidence.

Capsule endoscopy has been used in detecting carcinoid tumors of the small intestine. Guidelines from the National Comprehensive Cancer Network (NCCN, 2008) recommend the use of an Octreoscan for persons who present with carcinoid syndrome to determine tumor location and extent. Appendiceal tumors require abdominopelvic CT. Bronchoscopy, upper gastrointestinal barium swallow with small bowel follow through as indicated, colonoscopy and gastroscopy as indicated to identify the primary site. An MRI of the lung, mediastinum and head, and a CT scan of the chest, abdomen and pelvis may also be helpful, depending on the possible site. For work-up of carcinoid tumors of the small bowel, the NCCN guidelines recommend an initial evaluation with an Octreoscan and abdominopelvic CT scan.  For persons with locoregional disease, additional workup is recommended with a GI series with small bowel follow-through as indicated. Enteroclysis or capsule endoscopy are considered optional tests for work-up of locoregional disease of the small bowel.

Capsule endoscopy may also be useful for identifying celiac disease of the small intestine in persons with positive serologies where previous intestinal biopsies have been negative. Rondonotti et al (2007) found capsule endoscopy comparable to EGD for the diagnosis of celiac disease when there are overt villous changes. Consecutive patients with signs and symptoms suggestive of celiac disease and positive anti-gliadin and/or anti-endomysial and/or anti-tissue transglutaminase antibodies underwent upper gastrointestinal endoscopy and capsule endoscopy. Duodenal biopsies were classified according to modified Marsh's criteria. Capsule findings were evaluated for the presence of lesions compatible with celiac disease (scalloping of duodenal folds, fissures, flat mucosa, and mosaic appearance). Duodenal histology was normal in 11 and compatible with celiac disease in 32 of 43 patients studied. Using duodenal histology as the gold standard, the performance characteristics of capsule endoscopy for the diagnosis of celiac disease were: sensitivity 87.5 % (95 % confidence interval [CI]: 76.1 to 98.9 %), specificity 90.9 % (95 % CI: 81.0 to 100 %), positive predictive value 96.5 % (95 % CI: 90.1 to 100 %), negative predictive value 71.4 % (95 % CI:  55.8 to 87 %), positive and negative likelihood ratios 9.6 and 0.14, respectively. Eighteen patients had mucosal changes extending beyond the duodenum, involving the entire small bowel in three. These patients tended to have more severe symptoms, but the difference was not statistically significant. Interobserver agreement for the diagnosis of celiac disease by capsule endoscopy ranged between 79.2 and 94.4 %; kappa values ranged between 0.56 and 0.87. The authors concluded that capsule endoscopy shows good sensitivity and excellent specificity for the detection of villous atrophy in patients with suspected celiac disease.

Capsule endoscopy can be used for surveillance in persons with Peutz-Jeghers syndrome and other intestinal polyposis syndromes. An assessment of capsule endoscopy for the surveillance of persons with Peutz-Jeghers syndrome for the Australian Medical Service Advisory Committee (MSAC, 2007) recommended capsule endoscopy, performed no more than once in any two year period, for small bowel surveillance in patients diagnosed with Peutz-Jeghers syndrome. The assessment concluded that capsule endoscopy is a safe, well-tolerated procedure compared with small bowel surveillance by barium follow-through. The assessment stated that the small body of literature published on the clinical effectiveness of capsule endoscopy in small bowel surveillance of Peutz-Jeghers syndrome "limits the scope of analysis that can be performed to assess this technology." The MSAC found, however, that capsule endoscopy has changed management of persons with Peutz-Jeghers syndrome in situations where x-ray examinations have produced false negative results. The MSAC also found that capsule endoscopy for small bowel surveillance of Peutz-Jeghers syndrome is likely to be as effective and as cost-effective as small intestine x-ray.

Capsule endoscopy is also being investigated for detecting esophageal pathology. Given Imaging Ltd. (Yoqneam, Israel) received marketing clearance from the FDA in November 2004 for its Given Diagnostic System with PillCam ESO video capsule for imaging the esophagus. The PillCam ESO is being marketed for the diagnosis and evaluation of diseases of the esophagus such as gastroesophageal reflux disease (GERD), erosive esophagitis and Barrett's esophagus, a pre-cancerous condition. The FDA classified the PillCam ESO video capsule as a Class II device that is subject only to general regulatory controls.

The PillCam ESO is the same size as the PillCam SB (11 x 26 mm); however, miniaturization of electronics has enabled the PillCam ESO capsule to include 2 video cameras, 1 at each end of the capsule. Each imager captures 2 images per second, totaling 4 images per second. The esophageal transit time of the capsule is brief (less than 5 seconds) when patients ingest the capsule with water in the upright position. The transit time may be lengthened by having the patient ingest the capsule lying horizontally, which may allow visualization of the squamocolumnar junction.

In a feasibility study, Eliakim et al (2004) compared the PillCam ESO to conventional upper endoscopy as the gold standard for detection of esophageal pathologies in patients with suspected disorders of the esophagus (n = 17). Esophageal pathology was found in 12 of the patients by conventional upper endoscopy and with the PillCam ESO. An additional pathology that was found with the PillCam ESO was considered a false-positive. The authors concluded that this pilot study provides evidence that the esophageal capsule is an accurate, convenient, safe and well-tolerated method to screen patients for significant esophageal disorders; however, the authors stated that further, large-scale studies are necessary to fully assess this diagnostic tool.

A multi-center prospective study by the same investigator group, Eliakim et al (2005) compared the PillCam ESO to conventional upper endoscopy in patients with chronic GERD (n =  93) and Barrett's esophagus (n = 13). The PillCam ESO identified esophageal abnormalities in 61 of the 66 patients with positive esophageal findings (sensitivity, 92 %; specificity, 95 %). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the PillCam ESO for Barrett esophagus were 97 %, 99 %, 97 %, and 99 %, respectively, and for esophagitis 89 %, 99 %, 97 %, and 94 %, respectively. The authors reported no adverse events related to the PillCamESO during the 2-week follow-up period and concluded that it is a convenient and sensitive method for visualization of esophageal mucosal pathology and may provide an effective method to evaluate patients for esophageal disease. The authors reported that future generations of esophageal capsules with higher frame speed are in clinical trials.

The PillCam ESO is also being investigated for use in evaluating patients with esophageal varices.  Potential advantages of capsule endoscopy over EGD is the ability to avoid sedation in patients with liver cirrhosis, and the ability to perform capsule endoscopy during the office visit.  In a pilot study of 32 patients with cirrhosis, the PillCam ESO was compared with EGD in detecting esophageal varices and portal hypertensive gastropathy. A total of 23 patients had esophageal varices at both EGD and PillCam ESO evaluation (Eisen et al, 2006). The overall concordance between PillCam ESO and EGD was 96.9 % for the diagnosis of esophageal varices and 90.6 % for portal hypertensive gastropathy. 

De Franchis et al (2007) reported on a multi-center clinical trial comparing capsule endoscopy to EGD in detecting esophageal varices. Patients who were undergoing clinically indicated EGD for screening or surveillance of esophageal varices were asked to undergo capsule endoscopy prior to the EGD. EGD was performed within 48 hours of capsule endoscopy. A second investigator read each capsule endoscopy study, blinded to patient history and EGD results. A total of 285 patients underwent capsule endoscopy and EGD, 61 % of whom underwent the procedures for screening, and the remainder for surveillance of known esophageal varices. Sensitivity, specificity, positive predictive value and negative predictive value for capsule endoscopy compared to EGD were 86.7 %, 88.4 %, 92.9 %, and 79.1 %, respectively. Overall agreement was 87.3 % (95 % CI: 83 % to 91 %). There was complete agreement on varices grade in 82 % of cases. In 3 cases, capsule endoscopy did not detect esophageal varices that were considered medium/large on EGD, and EGD did not detect 1 case of medium esophageal varices seen on capsule endoscopy. In differentiating between 2 patient management alternatives (i.e., large varices which requires treatment and small varices or no varices which requires monitoring), sensitivity, specificity, positive predictive value and negative predictive value for capsule endoscopy compared to EGD were 84.6 %, 96.1 %, 89.2 % and 94.3 %, respectively. The overall agreement of treatment decisions based on esophageal varices size was 93 %.

Commenting on the study by de Franchis et al, Zaman (2008) stated that although the overall performance of esophageal capsule endoscopy was good, the study’s primary endpoint was not met -- capsule endoscopy was not equivalent to EGD for detecting varices. Zaman concluded that EGD should therefore continue to be the first-line modality for this application. However, capsule endoscopy should be considered an alternative modality if EGD is contraindicated because of concerns regarding safety or tolerance.

Lapalus and associates (2006) reported on a study comparing EGD and PillCam ESO in evaluating portal hypertension in 21 patients with cirrhosis. The PillCam ESO accurately assessed the presence or absence of esophageal varices in 17 of 20 patients (85 %). The 3 patients in whom there was a discrepancy between the 2 procedures were diagnosed with grade 1 varices on EGD and no varices on esophageal capsule endoscopy. The sensitivity of capsule endoscopy for detecting esophageal varices in comparison with EGD as the gold standard was 81.25 % (13 of 16), with a 100 % positive predictive value, a specificity of 100 % (12 of 12), and a negative predictive value of 57.1 % (4 of 7). In evaluating the stomach, 1 patient presented with gastric varices that were diagnosed with both EGD and capsule endoscopy. Portal hypertension gastropathy was diagnosed with EGD in 16 of 21 patients and with capsule endoscopy in 13 of 20 patients. The 4 patients in whom there was a discrepancy were diagnosed as having gastropathy on EGD but not on capsule endoscopy in 3 cases, or as having gastropathy on capsule endoscopy but not on EGD in 1 case.

Rubin et al (2011) reported on a randomized controlled clinical trial that found that use of esophageal capsule endoscopy to risk stratify emergency room patients with upper gastrointestinal bleeding (UGIB) significantly reduced time to emergent EGD and therapeutic intervention. A total of 24 patients with a history of UGIB within 48 hours of admission to the ER were randomized to esophageal capsule endoscopy versus standard clinical assessment. Esophageal capsule endoscopy was read real-time at the bedside and later reviewed after download. Positive capule endoscopy findings included coffee grounds, blood clot, red blood, or a bleeding lesion. Capsule endoscopy positive patients underwent EGD within 6 hours. Control patients and capsule endoscopy negative patients underwent EGD within 24 hours. Seven of 12 patients were capsule endoscopy positive. All 7 had confirmatory stigmata at EGD. Of the 5 capsule endoscopy negative patients, 4 had no stigmata at EGD and 1 was not endoscoped due to comorbidities. The actual lesion was visualized at capsule endoscopy in 4 of 12 patients during live view and in an additional 2 patients after download (6/12). Time to endoscopy in the capsule endoscopy positive group was significantly shorter than control patients (2.5 versus 8.9 hours, p = 0.029). There was no mortality. Blood transfusion requirement and length of stay were not significantly different in the 2 groups. Bjorkman (2010) stated that this was a very small study that had multiple limitations, including the potential for missing duodenal lesions, given that the capsule reached the duodenum in only 7 patients (58 %). The commentator also noted that many positive findings of capsule endoscopy (active bleeding, coffee grounds, and clots) can be identified with simple gastric aspiration. Bjorkman (2010) stated that the cost-effectiveness of esophageal capsule endoscopy in this setting is unclear.

Guidelines on the prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis from the American Association for the Study of Liver Diseases states the frequency of surveillance endoscopies in patients with no or smal varices depends upon their natural history (Garcia-Tsao et al, 2007). Upper endoscopy should be performed once the diagnosis is established. In patients with compensated cirrhosis who have no varices on screening endoscopy, upper endoscopy should be repeated in 2 to 3 year intervals. In those who have small varices, upper endoscopy should be repeated in 1 to 2 years. In the presence of decompensated cirrhosis, upper endoscopy should be repeated at yearly intervals.

An assessment by the American Society for Gastrointestinal Endoscopy (ASGE, 2006) found “[t]o date there are limited published data on capsule endoscopy of the esophagus…These preliminary data show an excellent diagnostic yield in cases of erosive esophagitis, Barrett's esophagus, and esophageal varices.”

The American College of Gastroenterology (ACG) (1999) recommends that patients with long-standing GERD symptoms, particularly those 50 years of age and older, undergo an upper endoscopy for evaluating the mucosa for esophagitis. Approximately 20 % of U.S. adults have symptoms of GERD at least once a week; however, a subgroup of patients with GERD develops severe complications that include erosive esophagitis, stricture formation, Barrett's esophagus, and adenocarcinoma of the esophagus. The ACG state that “patients with chronic GERD symptoms are those most likely to have Barrett's esophagus and should undergo upper endoscopy.” ACG guidelines state that the diagnosis of Barrett's esophagus requires biopsy to determine whether intestinal metaplasia is present. Tissue acquisition can be performed during conventional endoscopy for biopsy.

The PillCam ESO technique is limited because it: (i) does not have the capability of tissue acquisition, and (ii) the rapid transit rate through the esophagus could potentially miss suspected esophageal pathologies. Although Barrett's esophagus rarely progresses to adenocarcinoma (1 in 200 patients develop carcinoma per year), no studies have verified that any specific treatment or management strategy has decreased mortality rate from adenocarcinoma (Shalauta and Saad, 2004). Thus, the clinical effectiveness of the PillCam ESO as a potential screening method for suspected Barrett's esophagus is unclear. In addition, approximately 25 % of persons with Barrett's esophagus have no symptoms of reflux. Given the high prevalence of GERD, it may be prohibitive to screen all patients with GERD symptoms for the development of Barrett's metaplasia (Shalauta and Saad, 2004).

Thus, capsule endoscopy cannot completely replace conventional endoscopy for the evaluation of diseases involving the esophagus and its clinical value as a screening technique for suspected Barrett's esophagus remains unclear. The clinical effectiveness of the PillCam ESO in screening GERD patients for suspected Barrett's esophagus to direct appropriate patients for endoscopic biopsy needs to be demonstrated by large-scale clinical trials published in the peer-reviewed medical literature.

In a prospective, multi-center, blinded study, Lin and colleagues (2007) evaluated the accuracy of esophageal capsule endoscopy (ECE) for the diagnosis of Barrett's esophagus. Major outcome measures included sensitivity, specificity, as well as positive and negative predictive values of ECE for Barrett's esophagus by using EGD results, with histological confirmation as the criterion standard. A total of 96 subjects were enrolled, of whom 90 (94 %) completed the study, including 66 screening and 24 surveillance patients. Esophageal capsule endoscopy was 67 % sensitive and 84 % specific for identifying Barrett's esophagus, diagnosing 14 of 21 cases of biopsy-confirmed Barrett's esophagus. Positive and negative predictive values were 22 % and 98 %, respectively (calculated for screening patients only). Sensitivity for short- and long-segment Barrett's esophagus was similar. The authors concluded that the findings of this study showed that ECE had only moderate sensitivity and specificity for identifying Barrett's esophagus. They noted that ECE in its present form is unsuitable as a primary screening tool for Barrett's esophagus; however, ECE may be used in patients unwilling to undergo EGD.

Johnson (2007) noted that the findings by Lin et al (2007) are contradictory to the favorable results from the study by Eliakim et al (2005). This discrepancy is surprising because some earlier studies had been carried out with capsules that captured only 4 frames per second rather than the 14 frames per second captured by the capsule that was used in the present study. In the validation study, experts who were aware of both the endoscopy and the capsule findings adjudicated final diagnoses; as the current study did not include this protocol, its results could reflect "real-world" use more accurately. Although the convenience, safety, and patients’ tolerance of CE make it an attractive tool for esophageal imaging, at present, this device probably cannot be relied on for the one-time screening to exclude Barrett's esophagus in patients with chronic GERD.

Johnson (2008) commented that 2 recent studies (citing Sharma et al, 2008; Quershi et al, 2008) have demonstrated that esophageal capsule endoscopy is unreliable for detection of BE and has high interobserver variability, particularly with respect to short -segment BE (SSBE). Johnson (2008) concluded that these studies demonstrate that esophageal capsule endoscopy in its current form is not an adequate tool for screening for BE.

Sharma et al (2008) reported on a prospective trial involving 100 patients who had GERD symptoms or were under surveillance for BE. All patients underwent esophageal capsule endoscopy, followed by standard upper endoscopy, which was considered the gold standard. The esophageal capsule endoscopy findings were evaluated by investigators who were blinded to the endoscopic findings. BE was confirmed histologically in 45 of the 94 patients who completed the study. Esophageal capsule endoscopy demonstrated a sensitivity of 78 %, a specificity of 75 %, a positive predictive value of 74 %, and a negative predictive value of 79 %. The corresponding accuracy for diagnosing erosive esophagitis was 50 %, 90 %, 56 %, and 88 %, respectively.

Quershi et al (2008) reported on a prospective trial involving patients with short-segment BE (SSBE). A total of 20 patients with biopsy-proven SSBE underwent capsule endoscopy of the esophagus; images were subsequently reviewed by 2 experts who had no knowledge about the purpose of the study. Eighteen patients completed the study. BE was identified or suspected in 44 % of these patients by 1 observer but in only 16 % by the second observer. The Z-line was identified in all 18 patients by both observers, but there was agreement in only 6 as to whether it was normal or irregular.

American College of Gastroenterology guidelines do not support the use of esophageal capsule endoscopy for Barrett's esophagus (Wang et al, 2008).  

Capsule endoscopy has not been proven to be of value in detecting conditions in the colon. The major technical limitations of capsule colonoscopy are its requirement for highly effective bowel preparation and the limited frame speed of the current version. The colon is not well visualized with capsule endoscopy because stool obscures the visualization of the colonic mucosa. Visualization of the colon is more difficult than the small intestine because of its slower transit time and larger diameter; it is possible for the camera to miss suspicious areas of the colon simply by being pointed in the wrong direction. An American Cancer Society position statement (Levin et al, 2003) has concluded that there is no evidence to support the use of capsule endoscopy for detecting colorectal polyps or cancers.

Rex (2008) commented that capsule colonoscopy is similar to computed tomography colonography in having required polyp-size thresholds for referral for polypectomy. Rex stated that, from a cost-effectiveness standpoint, capsule colonoscopy is dominated by colonoscopy when equal adherence is assumed (citing Hassan et al, 2008). For capsule colonoscopy, improvements in adherence could overcome deficiencies in effectiveness (Rex, 2008). However, there currently is no good evidence of improved compliance with capsule colonoscopy. Thus, although capsule colonoscopy could improve adherence, actual demonstrations of whether and how much improvement could be expected are needed.

The Canadian Agency for Drugs and Technologies in Health (CADTH)'s report on capsule colonoscopy/PillCam Colon (Tran, 2007) stated that there is limited evidence on the use of this technology in imaging the colon. Two small, methodologically flawed pilot studies found that for patients with positive findings (i.e., abnormalities detected), the rates of detection with the PillCam Colon capsule were similar to those obtained with conventional colonoscopy. Larger, multi-center trials that compare CE with colonoscopy are needed. The evidence to support the use of CE in screening for colorectal cancer is also lacking.

In a prospective, multi-center study, Van Gossum and colleagues (2009) compared CE with optical colonoscopy (the standard for comparison) in a cohort of patients with known or suspected colonic disease for the detection of colorectal polyps or cancer. Patients underwent an adapted colon preparation, and colon cleanliness was graded from poor to excellent. These investigators computed the sensitivity and specificity of CE for polyps, advanced adenoma, and cancer. A total of 328 patients (mean age of 58.6 years) were included in the study. The capsule was excreted within 10 hours after ingestion and before the end of the lifetime of the battery in 92.8 % of the patients. The sensitivity and specificity of CE for detecting polyps that were 6 mm in size or bigger were 64 % (95 % CI: 59 to 72) and 84 % (95 % CI: 81 to 87), respectively, and for detecting advanced adenoma, the sensitivity and specificity were 73 % (95 % CI: 61 to 83) and 79 % (95 % CI: 77 to 81), respectively. Of 19 cancers detected by colonoscopy, 14 were detected by CE (sensitivity, 74 %; 95 % CI: 52 to 88). For all lesions, the sensitivity of CE was higher in patients with good or excellent colon cleanliness than in those with fair or poor colon cleanliness. Mild-to-moderate adverse events were reported in 26 patients (7.9 %) and were mostly related to the colon preparation. The authors concluded that the use of CE of the colon allows visualization of the colonic mucosa in most patients, but its sensitivity for detecting colonic lesions is low as compared with the use of optical colonoscopy.

In an editorial that accompanied the afore-mentioned article, Bretthauer (2009) stated that colonoscopy, CT colonography and colon CE (CCE) should be tested in randomized, comparative trials that allow valid and precise quantification of their effect on colorectal cancer (CRC) incidence and mortality.

Sieg et al (2009) stated that CRC screening with colonoscopy was introduced into the National Cancer Prevention Program in Germany in 2002. As compliance for screening is low (around 3 % per year), CCE could be an alternative approach. In this study, feasibility and performance of CCE were evaluated in comparison with colonoscopy in ambulatory patients with special attention to a short colon transit time. Colon CE was prospectively tested in ambulatory patients enrolled for colonoscopy who presented for screening or with positive fecal occult blood test. Study subjects underwent colon preparation and ingested the capsule in the morning. Colonoscopy was performed after excretion of the capsule. Colonoscopy and CCE were performed by independent physicians who were blinded to the results. A total of 38 patients were included. One patient was excluded because the capsule remained in the stomach during the entire period of examination. Another patient had limited time and the procedure had to be stopped when the capsule was still in the transverse colon. Thus, these investigators reported the results of 36 patients (30 men and 6 women; mean age of 56 years, range of 23 to 73 years) who successfully completed CCE and the conventional colonoscopy examination. The capsule was excreted within 6 hours in 84 % of the patients (median transit time 4.5 hours). If oral sodium phosphate was excluded from the preparation, the colon transit time increased to a median of 8.25 hours. In total, 7 of 11 small polyps (less than 6 mm) detected by colonoscopy were identified by CCE. One small polyp detected by CCE was not identified by colonoscopy. In this series, no large polyps were found. One CRC was detected by both methods. The mean rates of colon cleanliness (range from 1 = excellent to 4 = poor) in the cecum (2.1), transverse colon (1.6), and in the descending colon (1.5) were significantly better than in the rectosigmoid colon (2.6), and the overall mean rate during colonoscopy was significantly better than during CCE. No adverse effects occurred. The authors concluded that CCE appears to be a promising new modality for colonic evaluation and may increase compliance with CRC screening. To achieve a short colon transit time, sodium phosphate seems to be a necessary adjunct during preparation. The short transit time is a prerequisite to abandon the delay mode of the capsule. With an undelayed PillCam COLON capsule, a "pan-enteric" examination of the gastrointestinal tract would be possible. They stated that further studies are needed to improve the cleanliness, especially in the rectum and to evaluate the method as a potential screening tool.

In a retrospective case series, Triantafyllou and colleagues (2009) evaluated if PillCam colon capsule (PCC) endoscopy can complete colon examination after failure of conventional colonoscopy to visualize the cecum. By using PCC, these investigators studied 12 patients who had incomplete colonoscopy -- 6 patients had an obstructing tumor of the left side of the colon; and in 6 cases, there were technical difficulties to complete colonoscopy. PillCam colon capsule endoscopy visualized the rectum in 1 case. The capsule did not reach the site where colonoscopy stopped in 6 of the 12 cases, i.e., 3 left sited tumors and 3 with technical difficulties. Moreover, in 1 of the 3 cases in which the capsule passed the site where colonoscopy stopped, poor bowel preparation precluded the accurate examination of the colon. Four patients underwent a third colon examination (3 barium enemas and 1 virtual CT colonoscopy). There were no adverse events related to PCC endoscopy. The authors concluded that in this retrospective case series of patients with incomplete colonoscopy, PCC endoscopy did not always satisfactorily examine the colon.

In a meta-analysis evaluating the accuracy of CCE in detecting colon polyps, Rokkas et al (2010) concluded that CCE is a feasible alternative method for colon investigation, including screening for polyps and CRC, patients with incomplete colonoscopy, those with contraindications for conventional colonoscopy, or those unwilling to undergo colonoscopy because of its perceived inconvenience and discomfort. They stated that however, larger, multi-center, well-designed trials are needed to further establish the role of CCE in the evaluation of the large bowel in health and disease.

Spada et al (2010) noted that the PillCam colon capsule endoscopy (PCCE) represents one of the newest diagnostic, endoscopic technology designed to explore the colon. It is a non-invasive, swallowing colonoscope that is able to explore the colon without requiring sedation, nor radiation. The colon capsule measures 31 mm x 11 mm. It has dual cameras that enable to take pictures from both ends at a frame rate of 4 frames per second. The goal of PCCE is to substitute the conventional colonoscopy in the diagnosis of colonic diseases and to discriminate patients who deserve a conventional colonoscopy. The authors stated that although the preliminary results available in literature are encouraging, further studies are needed to confirm and increase the accuracy parameters and to select a more tolerable and effective regimen of preparation. In a review on alternatives to colonoscopy and their limitations, Chaput and co-workers (2010) stated that the PillCam for the small intestine has been adapted to study of the colon. Results of CCE studies are promising.

Capsule endoscopy is contraindicated in patients with known or suspected gastrointestinal obstruction, strictures, or fistulae. The available literature indicates that an upper gastrointestinal series should be performed prior to capsule endoscopy if the patient is suspected of having intestinal obstruction. In a review on contraindications to capsule endoscopy, Storch and Barkin (2006) stated that the only true remaining contraindications to capsule endoscopy are obstruction/pseudo-obstruction and pregnancy.

The Agile Patency System (Given Imaging, Ltd.) was cleared by the FDA through the 510k process for determining the presence of obstructions or strictures in the gastrointestinal tract through a dissolvable capsule. It supposedly will give physicians confidence that a PillCam video capsule will pass freely in a patient with known or suspected strictures. suspected strictures. Currently, there is insufficient evidence on the performance of this patency system as a technique to evaluate patients with known or suspected strictures prior to using the wireless capsule endoscopy system.

Spada et al (2007) evaluated the safety of the Pillcam in patients with known or suspected radiological stricture, previously tested for small bowel patency using the Given Patency capsule. A total of 27 patients (16 females, mean age of 44.2 years) with known or suspected intestinal stricture were enrolled prospectively: 24 had Crohn's disease, 2 had adhesive syndrome, and 1 had a suspected ischemic stricture. Patients underwent the Patency capsule test. In patients in whom the Patency capsule was excreted intact within 72 hours post-ingestion without occurrence of any adverse event, video capsule endoscopy (VCE) was performed to assess the presence of strictures or other gastrointestinal pathologies. The following parameters were evaluated: transit time of Patency capsules and/or tags from ingestion to excretion, condition of the Patency capsule at excretion, transit time of the Pillcam capsule, the ability of Pillcam capsule to detect intestinal strictures and small bowel pathologies, any adverse events. A total of 25 patients (92.6 %) retrieved the Patency capsule in the stools; 6 patients complained of abdominal pain, 4 of whom excreted a non-intact capsule. Hospitalization was required in 1 (4.3 %) patient with Crohn's disease due to occlusive syndrome. Fifteen patients (65.3 %) excreted an intact Patency capsule after a mean transit time of 25.6 hours without any adverse events. These 15 patients underwent the VCE successfully. The authors concluded that passage of an intact Patency capsule across a small bowel stricture provides direct evidence of functional patency of the gut lumen and allows a safe VCE. Intestinal strictures should not be considered an absolute contraindication for VCE.

Herrerias and colleagues (2008) assessed the ability of the Agile Patency System to help physicians identify which patients with known strictures may safely undergo CE. A total of 106 patients ingested the patency capsule. Fifty-nine (56 %) excreted it intact and subsequently underwent CE. There were no cases of capsule retention. Significant findings on CE were found in 24 (41 %). There were 3 severe adverse events. The authors concluded that these findings suggested that the Agile Patency System is a useful tool for physicians to use before CE in patients with strictures to avoid retention. This group of patients may have a high yield of clinically significant findings at CE. This capsule may determine whether patients who have a contraindication to CE may safely undergo CE and obtain useful diagnostic information.

The Agile Patency System has been reported to cause obstruction requiring urgent intervention. There is currently insufficient evidence from well-designed studies to support the use of the Agile Patency System. In addition, the American Society for Gastrointestinal Endoscopy's Technology Status Evaluation Report on wireless capsule endoscopy (Mishkin et al, 2006) stated that "[t]here is limited information about the new patency capsule. While it is intended to assess the passage of a capsule in patients at risk for intestinal stenosis, there have been reported cases that have required hospital admissions, augmentation of medical therapy, and even surgery. As a result, improvements to the system are being implemented before it can be approved in the United States".

In a randomized, controlled trial, Keller and colleagues (2010) assessed the safety and effectiveness of remote magnetic manipulation of a modified capsule endoscope (magnetic maneuverable capsule [MMC]; Given Imaging Ltd, Yoqneam, Israel) in the esophagus of healthy humans. A total of 10 healthy volunteers swallowed a conventional capsule (ESO2; Given Imaging) and a capsule endoscope with magnetic material, the MMC, which is activated by a thermal switch, in random order (1 week apart). An external magnetic paddle (EMP; Given Imaging) was used to manipulate the MMC within the esophageal lumen. MMC responsiveness was evaluated on a screen showing the MMC film in real time. Main outcome measurements included safety and tolerability of the procedure (questionnaire), responsiveness of the MMC to the EMP, esophageal transit time, and visualization of the Z-line. No adverse events occurred apart from mild retro-sternal pressure (n = 5). The ability to rotate the MMC around its longitudinal axis and to tilt it by defined movements of the EMP was clearly demonstrated in 9 volunteers. Esophageal transit time was highly variable for both capsules (MMC, 111 to 1,514 seconds; ESO2, 47 to 1,474 seconds), but the MMC stayed longer in the esophagus in 8 participants (p < 0.01). Visualization of the Z-line was more efficient with the ESO2 (inspection of 73 % +/- 18 % of the circumference versus 33 % +/- 27 %, p = 0.01). The authors concluded that remote control of the MMC in the esophagus of healthy volunteers is safe and feasible, but higher magnetic forces may be needed.

In an open clinical trial, Keller et al (2011) evaluated the safety and effectiveness of manipulation of a MMC in the human stomach by using a hand-held external magnet. A total of 10 healthy volunteers swallowed the MMC and sherbet powder for gastric distention. An EMP-2 was used to manipulate the MMC within the stomach. Responsiveness of the MMC was evaluated on a screen showing the MMC film in real time. Main outcome measurements included safety and tolerability (questionnaire), gastric residence time of the MMC, its responsiveness to the EMP-2, and visualization of gastric mucosa. There were no adverse events. The MMC was always clearly attracted by the EMP-2 and responded to its movements. It remained in the stomach for 39 +/- 24 minutes. In 7 subjects, both the cardia and the pylorus were inspected and 75 % or more of the gastric mucosa was visualized (greater than or equal to 50 % in all of the remaining subjects). A learning curve was clearly recognizable (identification of MMC localization, intended movements). The authors concluded that remote control of the MMC in the stomach of healthy volunteers using a hand-held magnet is safe and feasible. Responsiveness of the MMC was excellent, and visualization of the gastric mucosa was good, although not yet complete, in the majority of subjects. They stated that the system appeared to be clinically valuable and should be developed further.

Tong et al (2012) evaluated the diagnostic yield of CE, the characteristics predicting positive results, the presumed etiology of iron deficiency anemia (IDA) in negative⁄normal CE and patient management after CE.  A retrospective review of 934 patients who underwent CE between December 2001 and February 2010 was conducted.  All patients had undergone previous negative endoscopic examinations before CE.  Patients with IDA but no evidence of overt⁄occult bleeding were separated into 3 categories based on CE findings: (i) group A -- positive; (ii) group B -- negative⁄normal; and (iii) group C -- incomplete⁄indeterminate.  A total of 101 capsules in 97 patients were evaluated.  Group A had 25 subjects with positive findings on CE, 18 of whom were managed supportively.  Group B consisted of 69 subjects with negative⁄normal CE, 60 of whom were treated supportively.  Group C consisted of 3 subjects with incomplete CE results.  The authors concluded that in patients with IDA without evidence of GI bleeding, CE had a low diagnostic yield (25.7 %), which increased to 45.5 % after adjusting for low dietary iron intake and menorrhagia.  However, CE did not alter management in most patients regardless of findings, and many of the lesions requiring intervention were within reach of standard endoscopes.  No predictor of positive results was found.  In this patient population, careful history taking and thorough endoscopy could improve CE utilization, although its value is still relatively limited.

 
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
91110
91111
ICD-9 codes covered if selection criteria are met (for capsule endoscopy - esophagus through ileum):
209.00 - 209.03 Malignant carcinoid tumors of the small intestine
209.40 - 209.43 Benign carcinoid tumors of the small intestine
211.2 Benign neoplasm of duodenum, jejunum, ileum
280.0 Iron deficiency anemias, secondary to blood loss (chronic)
280.9 Iron deficiency anemia, unspecified
285.1 Acute posthemorrhagic anemia
288.8 Other specified disease of white blood cells
555.0 - 555.9 Regional enteritis [Crohn's disease]
558.1 - 558.9 Other and unspecified noninfectious gastroenteritis and colitis
578.0 - 578.9 Gastrointestinal hemorrhage
579.0 Celiac disease
759.6 Other hamartoses (Peutz-Jeghers syndrome)
780.60 Fever, unspecified
780.61 Fever presenting with conditions classified elsewhere
783.21 Abnormal loss of weight
787.91 Diarrhea
789.00 - 789.09 Abdominal pain
790.1 Elevated sedimentation rate
V67.59 Other follow-up examination [reevaluation of celiac disease]
ICD-9 codes covered if selection criteria are met (for capsule endoscopy - esophagus only):
456.0 - 456.1 Esophageal varices with bleeding or without mention of bleeding
456.20 Esophageal varices in diseases classified elsewhere, with bleeding
571.2 Alcoholic cirrhosis of liver
571.5 Cirrhosis of liver without mention of alcohol
571.6 Biliary cirrhosis
ICD-9 codes not covered for indications listed in the CPB (not all inclusive):
150.0 - 150.9 Malignant neoplasm of esophagus
152.0 - 153.9 Malignant neoplasm of small intestine, including duodenum, and colon
209.00 - 209.03 Malignant carcinoid tumors of the small intestine
209.10 - 209.17 Malignant neoplasm of the appendix, large intestine, and rectum
209.50 - 209.57 Benign carcinoid tumors of the appendix, large intestine, and rectum
211.3 Benign neoplasm of colon
288.61 Lymphocytosis (symptomatic) [duodenal lymphocytosis]
530.0 - 530.9 Diseases of esophagus
537.4 Fistula of stomach or duodenum
537.6 Hourglass stricture or stenosis of stomach
560.0 - 560.9 Intestinal obstruction without mention of hernia
562.10 - 562.13 Diverticula of colon
564.01 Slow transit constipation
564.1 Irritable bowel syndrome
564.7 Megacolon, other than Hirschsprung's
564.89 Other functional disorders of intestine
569.81 Fistula of intestine, excluding rectum and anus
579.0 Celiac disease
750.7 Other specified anomalies of stomach
751.1, 751.2 Atresia and stenosis of small intestine, or large intestine, rectum, and anal canal
751.5 Other anomalies of intestine [recurrent intussusception]
V76.50 - V76.52 Special screening for malignant neoplasm of intestine


The above policy is based on the following references:
  1. U.S. Food and Drug Administration (FDA), Office of Public Affairs. FDA approves camera pill to photograph small intestine. FDA Talk Paper T01-33. Rockville, MD: FDA; August 1, 2001. Available at: http://www.fda.gov/bbs/topics/ANS WERS/2001/ANS01094.html. Accessed January 10, 2001.
  2. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health. Given Diagnostic Imaging System. K010312. Rockville, MD: FDA; August 21, 2001. Available at: http://www.fda.gov/cdrh/mda/docs/k010312.pdf. Accessed January 10, 2001.
  3. Appleyard M, Glukhovsky A, Swain P. Wireless-capsule diagnostic endoscopy for recurrent small bowel bleeding [letter]. N Engl J Med. 2001;344:232-233.
  4. Fischer D, Schreiber R, Meron G, et al. Localization of a wireless capsule endoscope in the GI tract [abstract]. Gastrointest Endosc. 2001;53:AB126.
  5. Fischer HA, Lo SK, Deleon VP. Gastrointestinal transit of the wireless endoscopic capsule [abstract]. Gastrointest Endosc. 2002;55:AB134.
  6. Jacob H, Levy D, Schreiber R, et al. Localization of the Given M2A ingestible capsule in the Given Diagnostic Imaging System [abstract]. Gastrointest Endosc. 2002;55:AB135.
  7. Lewis B, Swain P. Capsule endoscopy in the evaluation of patients with suspected small intestinal bleeding, a blinded analysis: The results of the first clinical trial [abstract]. Gastrointest Endosc. 2001;53:AB70.
  8. Lewis BS, Swain P. Capsule endoscopy in the evaluation of patients with suspected small intestinal bleeding: Results of a pilot study. Gastrointest Endosc. 2002;56(3):349-353.
  9. Costamagna G, Shah SK, Riccioni ME, at al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. Gastroenterology. 2002;123(4):999-1005.
  10. Faigel DO, Fennerty MB. 'Cutting the cord' for capsule endoscopy. Gastroenterology. 2002:123(4):1385-1388.
  11. Scapa E, Meron G, Glukhovsky A, et al. Wireless capsule colonoscopy [abstract]. Gastrointest Endosc. 2001;53:AB111.
  12. Selby WS, Shackell N. A Comparison between the M2A™ Capsule and push enteroscopy for the investigation of obscure gastrointestinal bleeding [abstract]. J Gastroenterol Hepatol. 2001;16 Suppl:A29.
  13. Appleyard M, Fireman Z, Glukhovsky A, et al. A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions [canine study]. Gastroenterology. 2000;119:1431-1438.
  14. Appleyard M, Glukhovsky A, Jacob H, et al. Studies of gastric and small bowel transit times of video capsule endoscopes [abstract]. Endoscopy. 2000;32 (Suppl1).
  15. Bradbury J. Journey to the center of the body [news]. Lancet. 2000;356(9247).
  16. Gong F, Swain P, Mills T. Wireless endoscopy. Gastrointest Endosc. 2000;51(6):725-729.
  17. Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy [news]. Nature. 2000;405:417.
  18. Meron G. The development of the swallowable video capsule (M2A). Gastrointest Endosc. 2000;6:817-819.
  19. Given Imaging Inc. Given Imaging: Expanding the Scope of GI [website]. Norcross, GA: Given; 2001. Available at: http://www.givenimaging.com. Accessed January 10, 2001.
  20. Given Imaging Inc. PillCam™ ESO Capsule Endoscopy [website]. Atlanta, GA. Available at: http://www.givenimaging.com/Cultures/en-US/Given/English/Products/ESO_CE/. Accessed April 12, 2005.
  21. Letter from Daniel G Schultz, Deputy Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Rockville, MD, to Jonathan S. Kahan, Hogan & Hartson, L.L.P., Washington, DC, Re: K010312, Evaluation of Class III Designation (de Novo), August 1, 2001.
  22. Zuckerman GR, Prakash C, Askin MP, Lewis BS.. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology. 2000;118(1):201-221.
  23. American Gastroenterological Association medical position statement: Evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology. 2000;118(1):197-200 (reviewed 2001).
  24. Leighton JA, Sharma VK, Yousfi M, et al. Video capsule endoscopy (VCE): New information and limitations defined [abstract]. Gastrointest Endosc. 2002;55:AB134.
  25. Pennazio M, Santucci R, Rondonotti E, et al. Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: Results of the Italian multicentre experience [abstract]. Gastrointest Endosc. 2002;55:AB87.
  26. Swain PC, Mosse A, Burke P, et al. Remote propulsion of wireless capsule endoscopes [abstract]. Gastrointest Endosc. 2002;55:AB88.
  27. Ell C, Remke S, May A, et al. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy. 2002;34(9):685-689.
  28. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53:44-55.
  29. Alberta Heritage Foundation for Medical Research (AHFMR). Ingestible imaging capsule. Technote. Edmonton, AB: AHFMR; 2000.
  30. Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT). Wireless capsule endoscopy for bowel examination - systematic review, expert panel. Paris, France: CEDIT; 2001.
  31. Costa V, Brophy J. Should the MUHC approve the video capsule endoscopy system in the diagnosis of small bowel abnormalities?. Montreal, QC: Technology Assessment Unit of the McGill University Health Centre (MUHC); 2003.
  32. National Horizon Scanning Centre (NHSC). M2A capsule endoscopy for the diagnosis of small bowel disorders - horizon scanning review. Birmingham, UK: NHSC; 2002.
  33. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Wireless capsule endoscopy. TEC Assessment Program. Chiacao, IL: BCBSA: February 2003;17(21). Available at: http://www.bcbs.com/tec/vol17/17_21.html. Accessed August 19, 2005.
  34. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Wireless capsule endoscopy for small-bowel diseases other than obscure GI bleeding. TEC Assessment Program. Chicago, IL: BCBSA; December 2003; 18(18). Available at: http://www.bcbs.com/tec/vol18/18_18.html. Accessed February 5, 2004.
  35. Dubcenco E, Jeejeebhoy KN, Tang SJ, Baker JP. The value of capsule endoscopy in the diagnosis and management of Crohn's disease: Report of two cases. Gastrointest Endosc. 2004;59(2):314-316.
  36. Liangpunsakul S, Mays L, Rex DK. Performance of given suspected blood indicator. Am J Gastroenterol. 2003;98(12):2676-2678.
  37. Sriram P, Rao G, Reddy D. Wireless capsule endoscopy: Experience in a tropical country. J Gastroenterol Hepatol. 2004;19(1):63-67.
  38. Annibale B, Capurso G, Baccini F, et al. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig Liver Dis. 2003;35(11):784-787.
  39. de Franchis R, Rondonotti E, Abbiati C, et al. Capsule enteroscopy in small bowel transplantation. Dig Liver Dis. 2003;35(10):728-731.
  40. Van Gossum A, Hittelet A, Schmit A, et al. A prospective comparative study of push and wireless-capsule enteroscopy in patients with obscure digestive bleeding. Acta Gastroenterol Belg. 2003;66(3):199-205.
  41. Hara AK, Leighton JA, Sharma VK, Fleischer DE. Small bowel: Preliminary comparison of capsule endoscopy with barium study and CT. Radiology. 2004;230(1):260-265.
  42. Neu B, Wettschureck E, Rosch T. Is esophageal capsule endoscopy feasible? Results of a pilot. Endoscopy. 2003;35(11):957-961.
  43. de Franchis R, Avesani EM, Abbiati C, et al. Unsuspected ileal stenosis causing obscure GI bleeding in patients with previous abdominal surgery--diagnosis by capsule endoscopy: A report of two cases. Dig Liver Dis. 2003;35(8):577-584.
  44. Ang TL, Fock KM, Ng TM, et al. Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J Gastroenterol. 2003;9(10):2313-2316.
  45. de Mascarenhas-Saraiva MN, da Silva Araujo Lopes LM. Small-bowel tumors diagnosed by wireless capsule endoscopy: Report of five cases. Endoscopy. 2003;35(10):865-868.
  46. Madisch A, Schimming W, Kinzel F, et al. Locally advanced small-bowel adenocarcinoma missed primarily by capsule endoscopy but diagnosed by push enteroscopy. Endoscopy. 2003;35(10):861-864.
  47. Bardan E, Nadler M, Chowers Y, et al. Capsule endoscopy for the evaluation of patients with chronic abdominal pain. Endoscopy. 2003;35(8):688-689.
  48. Ciorba MA, Prakash C. Wireless capsule endoscopy in the diagnosis of small bowel Crohn's disease. Inflamm Bowel Dis. 2003;9(4):276.
  49. Mylonaki M, Fritscher-Ravens A, Swain P. Wireless capsule endoscopy: A comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding. Gut. 2003;52(8):1122-1126.
  50. Saurin JC, Delvaux M, Gaudin JL, et al. Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: Blinded comparison with video push-enteroscopy. Endoscopy. 2003;35(7):576-584.
  51. Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut. 2003;52:390-392.
  52. Fleischer DE, Leighton JA, Sharma VK, et al. Video capsule endoscopy (VCE) is useful in the evaluation of unexplained abdominal pain (AP) [abstract]. Gastroenterology, 2003;124(1 Suppl 1):A245.
  53. Bloom PD, Rosenberg MD, Klein SD, et al. Wireless capsule endoscopy (CE) is more informative than ileoscopy and SBFT for the evaluation of the small intestine (SI) in patients with known or suspected Crohn's disease [abstract]. Gastroenterology, 2003;124(1 Suppl 1):A203.
  54. Buchman AL, Miller F, Wallin A. Videocapsule endoscopy: A blinded comparison to small bowel contrast study in the diagnosis of Crohn's disease [abstract]. DDW Meeting. 2003. Available at: http://ddw03.agora.com/planner/displayabstract.asp?presentationid=25188. Accessed February 5, 2004.
  55. Chong AKH, Taylor ACF, Miller AM, et al. Initial experience with capsule endoscopy at a major referral hospital. MJA. 2003;178:537-540.
  56. Eliakim R, Fischer D, Suissa A, et al. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease. Eur J Gastroenterol Hepatol, 2003;15:363-367.
  57. Herrerias JM, Caunedo A, Rodriguez-Tellez M, et al. Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy. Endoscopy, 2003;35(7):564-568.
  58. Heigh RI, Leighton JA, Hara A et al. (2003). Diagnosing small bowel (SB) Crohn's disease (CD): Video capsule endoscopy (VCE) and CT enterography (CTE) lead the way; Small bowel follow through (SBFT) less helpful [abstract]. Gastroenterology, 2003;124 (1 Suppl 1):A37.
  59. Liangpunsakul S, Chadalawada V, Rex DK, et al. Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis. Am J Gastroenterol. 2003;98:1295-1298.
  60. Sant'anna AMGD, Miron MC, Dubois J, et al. Wireless capsule endoscopy for obscure small bowel disorders: Final results of the first pediatric trial [abstract]. AGA Abstracts. 2003;139:A17.
  61. Petroniene R, Dubcenco E, Baker JP, et al. Performance evaluation of the Given Diagnostic Imaging System in diagnosing celiac disease [abstract]. AGA Abstracts. 2002;M1653:A329.
  62. Scapa E, Jacob H, Lewkowicz S, et al. Initial experience of wireless-capsule endoscopy for evaluating occult gastrointestinal bleeding and suspected small bowel pathology. Am J Gastroenterol, 2002;97(11):2776-2779.
  63. Brodsky L, Wireless capsule endoscopy. Emerging Issues in Health Technologies. Issue 53. Ottawa, ON: Canadian Coordinating Office of Health Technology Assessment (CCOHTA); December 2003.
  64. Medical Services Advisory Committee (MSAC). M2A capsule endoscopy for the evaluation of obscure gastrointestinal bleeding in adult patients. Assessment Report. MSAC Application 1057. Canberra, ACT; MSAC; August 2003.
  65. National Institute for Clinical Excellence (NICE). Wireless capsule endoscopy. Interventional Procedure Consultation Document. London, UK: NICE; July 2004.
  66. Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat. Wireless capsule endoscopy. Health Technology Scientific Literature Review. Toronto, ON: Ontario Ministry of Health and Long-Term Care; April 2003.
  67. California Technology Assessment Forum (CTAF). Capsule endoscopy for evaluation of occult bleeding. Technology Assessment. San Francisco, CA: CTAF; October 16, 2002. Available at: http://ctaf.org/ass/viewfull.ctaf?id=5815322310. Accessed September 19, 2005.
  68. Pennazio M, Santucci R, Rondonotti E, et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: Report of 100 consecutive cases. Gastroenterology. 2004;126(3):643-653.
  69. Ginsberg GG, Barkun AN, Bosco, JJ, et al.; American Society for Gastrointestinal Endoscopy Technology Assessment Committee. Wireless capsule endoscopy. Technology Assessment. Oak Brook, IL: American Society for Gastrointestinal Endoscopy; August 2002. Available at: http://www.askasge.org/pages/tech/nt_cap_endo.cfm#indi. Accessed August 19, 2005.
  70. Eliakim R, Yassin K, Shlomi I, et al. A novel diagnostic tool for detecting oesophageal pathology: The PillCam oesophageal video capsule. Aliment Pharmacol Ther. 2004;20(10):1083-1089.
  71. Shalauta MD, Saad R. Barrett's esophagus. Am Fam Physician. 2004;69(9):2113-2118.
  72. Saurin JC, Delvaux M, Vahedi K, et al. Clinical impact of capsule endoscopy compared to push enteroscopy: 1-year follow-up study. Endoscopy. 2005;37(4):318-323.
  73. Kalantzis N, Papanikolaou IS, Giannakoulopoulou E, et al. Capsule endoscopy; the cumulative experience from its use in 193 patients with suspected small bowel disease. Hepatogastroenterology. 2005;52(62):414-419.
  74. Sampliner RE . The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's Esophagus. Am J Gastroenterol. 2002;97(8):1888-1895. Available at: http://www.acg.gi.org/physicians/guidelines/BarrettsEsophagus.pdf. Accessed April 13, 2005.
  75. DeVault KR, Castell DO. The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999;94(6):1434-1442. Available at: http://www.acg.gi.org/physicians/guidelines/GERDTreatment.pdf. Accessed April 13, 2005.
  76. Golding MI, Doman DB, Goldberg, HJ. Take your Pill(Cam): It might save your life. Gastrointest Endosc. 2005;62(1):196-198.
  77. Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005;39(7):572-578.
  78. National Institute for Clinical Excellence (NICE). Wireless capsule endoscopy for investigation of the small bowel. Interventional Procedure Guidance 101. London, UK: NICE; December 2004. Available at: http://www.nice.org.uk/page.aspx?o=235704. Accessed September 19, 2005.
  79. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol. 2005;100(11):2407-2418.
  80. Varela Lema L, Ruano-Ravina A. Diagnostic effectiveness, security and clinical usefulness of capsule endoscopy in the diagnosis of small bowel disorders [summary]. INF2005/04. Santiago de ComPostela, Spain: Galician Agency for Health Technology Assessment (AVALIA-T); 2005.
  81. Pichon Riviere A, Augustovski F, Alcaraz A, et al. Usefulness of video capsule gastrointestinal endoscopy in digestive bleeding of unknown origin. Report IRR No. 56. Buenos Aires, Argentina: Institute for Clinical Effectiveness and Health Policy (IECS); 2005.
  82. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol. 2006;101(5):954-964.
  83. Storch I, Barkin JS. Contraindications to capsule endoscopy: Do any still exist? Gastrointest Endosc Clin N Am. 2006;16(2):329-336.
  84. American Society for Gastrointestinal Endoscopy (ASGE). ASGE Technology Status Evaluation Report: Wireless capsule endoscopy. Gastrointest Endosc. 2006;63(4):539-545.
  85. Eisen GM, Eliakim R, Zaman A, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: A prospective three-center pilot study. Endoscopy. 2006;38:31-35.
  86. Lapalus MG, Dumortier J, Fumex F, et al. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: A prospective comparative study of performance and tolerance. Endoscopy. 2006;38:36-41.
  87. Poelmans J, Hulstaert F, Huybrechts M, Ramaekers D. Capsule endoscopy. Brussels, Belgium: Belgian Health Care Knowledge Centre (KCE); 2006. Available at: http://www.library.nhs.uk/gastroliver/ViewResource.aspx?resID=257045. Accessed July 31, 2007.
  88. Lin OS, Schembre DB, Mergener K, et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett’s esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc. 2007; 65(4):577-583.
  89. Johnson DA. Screening for BE: Capsule vs. standard endoscopy. Journal Watch Gastroenterology. July 6, 2007. Available at: http://gastroenterology.jwatch.org/cgi/content/full/2007/706/1. Accessed July 31, 2007.
  90. Mazzarolo S, Brady P. Small bowel capsule endoscopy: A systematic review. South Med J. 2007;100(3):274-280.
  91. De Franchis R, Eisen GM, Eliakim AR, et al. Esophageal capsule endoscopy (Pillcam ESO) is comparable to traditional endoscopy for detection of esophageal varices -- an international multi-center clinical trial [abstract]. Gastrointest Endosc. 2007;65(5):AB107.
  92. Garcia-Tsao G, Sanyal AJ, Grace ND, et al.; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. AASLD Practice Guidelines. Hepatology. 2007;46(3):922-938.
  93. Mishkin DS, Chuttani R, Croffie J, et al; Technology Assessment Committee, American Society for Gastrointestinal Endoscopy. ASGE Technology Status Evaluation Report: Wireless capsule endoscopy. Gastrointest Endosc. 2006;63(4):539-545.
  94. Tran K. Capsule colonoscopy: PillCam® Colon. Issues in Emerging Health Technologies. Issue 106. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007. Available at: http://www.cadth.ca/media/pdf/E0034_PillCam-Colon_cetap_e.pdf. Accessed July 21, 2008.
  95. de Leusse A, Vahedi K, Edery J, et al. Capsule endoscopy or push enteroscopy for first-line exploration of obscure gastrointestinal bleeding? Gastroenterology. 2007;132(3):855-862.
  96. Raju GS, Gerson L, Das A, Lewis B; American Gastroenterological Association. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology. 2007;133(5):1694-1696.
  97. Spada C, Shah SK, Riccioni ME, et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007;41(6):576-582. 
  98. Rondonotti E, Spada C, Cave D, et al. Video capsule enteroscopy in the diagnosis of celiac disease: A multicenter study. Am J Gastroenterol. 2007;102(8):1624-1631.
  99. Herrerias JM, Leighton JA, Costamagna G, et al. Gastrointest Endosc. 2008;67(6):902-909.
  100. Zaman A. ECE vs. EGD for detection of esophageal varices. Summary and Comment. Journal Watch Gastroenterology, July 25, 2008.
  101. Rex DK. Cost-effectiveness of capsule colonoscopy for CRC screening. Summary and comment. Journal Watch Gastroenterology, August 1, 2008.
  102. Hassan C, et al. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer. Endoscopy. 2008;40:414. 
  103. Sharma P, et al. The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett’s esophagus: A blinded, prospective study. Am J Gastroenterol. 2008;103:525.
  104. Qureshi WA, et al. Capsule endoscopy for screening for short-segment Barrett’s esophagus. Am J Gastroenterol. 2008;103:533.
  105. Johnson DA. How effective is ECE screening for BE? Summary and Comment. Journal Watch Gastroenterology, July 3, 2008.
  106. National Comprehensive Cancer Network (NCCN). Neuroendocrine tumors. NCCN Clinical Practice Guidelines in Oncology v.1.2008. Fort Washington, PA: NCCN; 2008.
  107. Medical Services Advisory Committee (MSAC). Review of application of PillCam® capsule endoscopy (formerly known as M2A®) for the surveillance of Peutz-Jeghers syndrome. Assessed by IMS Health, Sydney. Canberra, ACT: MSAC; October 25, 2007.
  108. Medical Services Advisory Committee (MSAC). Capsule endoscopy for Peutz-Jeghers syndrome. MSAC Application 1119. Canberra, ACT: MSAC; 2008.
  109. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: A prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255-266.
  110. Lu Y, Gao R, Liao Z, et al. Meta-analysis of capsule endoscopy in patients diagnosed or suspected with esophageal varices. World J Gastroenterol. 2009;15(10):1254-1258.
  111. Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104(6):1533-1539.
  112. Van Gossum A, Navas MM, Fernandez-Urien I, et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med. 2009;361(3):264-270.
  113. Bretthauer M. The capsule and colorectal-cancer screening--the crux of the matter. N Engl J Med. 2009;361(3):300-301.
  114. Sieg A, Friedrich K, Sieg U. Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. Am J Gastroenterol. 2009;104(4):848-854.
  115. Cohen SA, Gralnek IM, Ephrath H, et al. Capsule endoscopy may reclassify pediatric inflammatory bowel disease: A historical analysis. J Pediatr Gastroenterol Nutr. 2008;47(1):31-36.
  116. American College of Radiology (ACR). Crohn’s disease. ACR Appropriateness criteria. 2008.
  117. Sidhu R, Sanders DS, Morris AJ, McAlindon ME. Guidelines on small bowel enteroscopy and capsule endoscopy in adults. Gut. 2008;57:125-136.
  118. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: A global perspective. WGO Global Guideline. June 2009.
  119. Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104(6):1533-1539.
  120. Leighton JA, Gralnek IM, Richner RE, et al. Capsule endoscopy in suspected small bowel Crohn's disease: Economic impact of disease diagnosis and treatment. World J Gastroenterol. 2009;15(45):5685-5692.
  121. Gralnek IM, Leighton JA, Papatheofanis F. Evidence for capsule endoscopy in suspected small bowel Crohn's disease: An evaluation of inter-grading system concordance. J Insur Med. 2009;41:270-283.
  122. Alexander JA, Leighton JA. Capsule endoscopy and balloon-assisted endoscopy: competing or complementary technologies in the evaluation of small bowel disease? Curr Opin Gastroenterol. 2009;25(5):433-437.
  123. El-Matary W, Huynh H, Vandermeer B. Diagnostic characteristics of given video capsule endoscopy in diagnosis of celiac disease: A meta-analysis. J Laparoendosc Adv Surg Tech A. 2009;19(6):815-820.
  124. Triantafyllou K, Tsibouris P, Kalantzis C, et al. PillCam Colon capsule endoscopy does not always complement incomplete colonoscopy. Gastrointest Endosc. 2009;69(3 Pt 1):572-576.
  125. Rokkas T, Papaxoinis K, Triantafyllou K, Ladas SD. A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps. Gastrointest Endosc. 2010;71(4):792-798.
  126. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: A meta-analysis. Am J Gastroenterol. 2010;105(6):1240-1248.
  127. Rubin M,  Hussain SA, Shalamov A, et al. Live view video capsule endoscopy enables risk stratification of patients with acute upper GI bleeding in the emergency room: A pilot study. Dig Dis Sci. 2011;56(3):786-791.
  128. Bjorkman DJ. Video capsule endoscopy for patients with upper gastrointestinal bleeding. VCE screening accurately identified high-risk patients and shortened their wait times for urgent endoscopy but at what cost? Summary and Comment. JWatch Gastroentrol. September 10, 2010.
  129. Saurin JC, Pilleul F, Soussan EB, et al.; Capsule Commission of the French Society of Digestive Endoscopy (SFED). Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy. 2010;42(12):1057-1062. 
  130. Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: Is it time for surveillance? Lancet Oncol. 2008;9(9):901-905.
  131. Spada C, Riccioni ME, Hassan C, Costamagna G. PillCam capsule endoscopy for the diagnosis of colonic diseases. Recenti Prog Med. 2010;101(6):227-231.
  132. Chaput U, Oudjit A, Prat F, Chaussade S. Alternatives to colonoscopy and their limitations. Presse Med. 2010;39(4):437-445.
  133. Keller J, Fibbe C, Volke F, et al. Remote magnetic control of a wireless capsule endoscope in the esophagus is safe and feasible: Results of a randomized, clinical trial in healthy volunteers. Gastrointest Endosc. 2010;72(5):941-946.
  134. Keller J, Fibbe C, Volke F, et al. Inspection of the human stomach using remote-controlled capsule endoscopy: A feasibility study in healthy volunteers (with videos). Gastrointest Endosc. 2011;73(1):22-28.
  135. Rokkas T, Niv Y. The role of video capsule endoscopy in the diagnosis of celiac disease: A meta-analysis. Eur J Gastroenterol Hepatol. 2012;24(3):303-308.
  136. Tong J, Svarta S, Ou G, et al. Diagnostic yield of capsule endoscopy in the setting of iron deficiency anemia without evidence of gastrointestinal bleeding. Can J Gastroenterol. 2012;26(10):687-690.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top